Relief Therapeutics and its U.S. partner, NeuroRx announced NeuroRx has completed final manufacturing of investigational drug RLF-100 for Phase 2b/3 clinical trial to assess intravenous RLF-100 as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients on mechanical ventilation. Read more...
SubjectWell has developed a growing patient registry of individuals in the US interested in participating in clinical trials for a COVID-19 vaccine as these trials become more widely available. In three weeks, 10,000 people from SubjectWell’s patient network have already opted into the list, with approximately 70,000 individuals expected to register by the end of May. Read more...
Hetero has entered into a licensing agreement with Gilead Sciences for the manufacturing and distribution of Remdesivir for the treatment of Covid-19. Read more...
Exyte and Univercells Technologies are announcing a global partnership for optimized construction of modular standardized and flexible GMP manufacturing facilities for vaccines. Read more...